Bristol-Myers Squibb Co Stock Price, News & Analysis

Exelixis has expanded its collaboration with Bristol-Myers Squibb to include a fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial. This trial is evaluating XL092, Exelixis' next-generation oral tyrosine kinase inhibitor (TKI), combined with immune checkpoint inhibitors for advanced solid tumors. The study aims to determine the optimal dosing regimen across various combinations, enhancing treatment options for patients.

Bristol Myers Squibb (BMY) has received European Commission approval for Opdualag, a first-in-class combination treatment of nivolumab and relatlimab, for advanced melanoma in patients aged 12 and older with PD-L1 expression < 1%. This breakthrough comes from the RELATIVITY-047 trial, which showed Opdualag more than doubled median progression-free survival (PFS) to 6.7 months compared to 3.0 months for nivolumab alone. No new safety concerns were identified. This approval marks a significant advancement in melanoma treatment options within the EU, expanding patient access across member states.

Bristol Myers Squibb (NYSE: BMY) announced that the Phase 3 CheckMate -76K trial for Opdivo (nivolumab) in stage IIB/C melanoma has met its primary endpoint with a significant improvement in recurrence-free survival at a pre-specified interim analysis. The trial showed no new safety signals. Approximately one-third of stage IIB and half of stage IIC melanoma patients may experience recurrence within five years post-surgery. Opdivo's results offer potential advancements in cancer treatment, targeting earlier disease stages to improve patient outcomes.

Bristol Myers Squibb (NYSE: BMY) has announced a quarterly dividend of $0.54 per share, payable on November 1, 2022, to stockholders of record by October 7, 2022. Additionally, a dividend of $0.50 per share on its convertible preferred stock will be paid on December 1, 2022, to stockholders on record by November 8, 2022. This decision reflects the company's commitment to returning value to its shareholders while supporting its mission to develop innovative medicines.

Bristol Myers Squibb (NYSE:BMY) announced positive two-year results from the POETYK PSO long-term extension trial for Sotyktu™ (deucravacitinib), showing maintained efficacy in treating moderate-to-severe plaque psoriasis. Response rates at 112 weeks were 82.4% for PASI 75 and 55.2% for PASI 90. The data were presented at the 2022 European Academy of Dermatology and Venereology Congress, underscoring the company's commitment to dermatology research. These findings support Sotyktu’s role as a promising oral therapy for patients with psoriasis.

Bristol Myers Squibb's Sotyktu™ (deucravacitinib) has received FDA approval as the first oral, selective TYK2 inhibitor for adults with moderate-to-severe plaque psoriasis, marking a significant innovation in treatment options after nearly a decade. The approval follows successful Phase 3 POETYK PSO clinical trials, which showed Sotyktu's superior efficacy over placebo and Otezla® in achieving skin clearance. This breakthrough therapy is anticipated to set a new standard of care and will be available to patients starting September 2022.

Bristol Myers Squibb (NYSE: BMY) is launching its annual Coast 2 Coast 4 Cancer ride, starting from Cannon Beach, Oregon and ending in Long Branch, New Jersey on October 3. Over 126 employees will participate to raise awareness and funding for the V Foundation for Cancer Research. The event has raised over $9.83 million since its inception in 2014, with a target of surpassing $1 million this year. Participants include cancer survivors and those riding in memory of loved ones, with Bristol Myers Squibb matching donations up to $500,000.

Bristol Myers Squibb (NYSE:BMY) will announce its third-quarter 2022 financial results on October 26, 2022, during a conference call at 8:00 a.m. ET. The call will include a review of the financial results and a Q&A session with investors and analysts. A live webcast is available for the public at investor.bms.com. The call can also be accessed via phone by dialing 877-502-9276 in the U.S. Participants can replay the call starting 11:30 a.m. ET on the same day until November 9, 2022.

Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 8:10 a.m. ET in New York City. Executive Vice Presidents Chris Boerner, Ph.D., and Samit Hirawat, M.D., will address questions regarding the company's operations. A live webcast will be accessible at investor.bms.com, with an archived version available later that day.

Bristol Myers Squibb focuses on developing innovative medicines for serious diseases.